The program in question is Neuphoria’s BNC210, also known as soclenicant, an α7 nicotinic receptor negative alteration ...

Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.

IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through IND-enabling studies ...

Infectious diseases can have very different effects on different people; some individuals may have virtually no symptoms from COVID-19, for example, while others are killed by the viral disease.

Akari Therapeutics is advancing its research on a novel spliceosome modulator, PH1, which has shown potential in killing cancer cells and activating the immune system. The company is focusing on the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--HyperLight, creator of the TFLN Chiplet™ platform, today announced the launch of its groundbreaking 110 GHz Low Vπ Intensity Modulator, featuring industry-standard ...

Thursday, Corcept Therapeutics Incorporated (NASDAQ:CORT) released announced preliminary results from the prevalence phase of its ongoing CATALYST study of Cushing’s syndrome (hypercortisolism) in ...

Durability of immune checkpoint inhibitor (ICI) response following treatment discontinuation in advanced merkel cell carcinoma (MCC). The 15-gene expression profile test is independent from PRAME and ...

imec says its achievement combines two world firsts: the first demonstration of a beyond-110GHz GeSi EAM operating in the ...